O7.5. LONG-TERM SAFETY AND TOLERABILITY OF BREXPIPRAZOLE IN PATIENTS WITH SCHIZOPHRENIA

por Hakala, Mika, Gislum, Mette, Skuban, Aleksandar, Meehan, Stine
Publicado 2018

PS155. Long-term safety of adjunctive brexpiprazole (OPC-34712) in MDD: results from two 52-week open-label studies

por Nelson, Craig, Skuban, Aleksandar, Zhang, Peter, Weiller, Emmanuelle, Weiss, Catherine
Publicado 2016

PM385. Long-term safety of brexpiprazole (OPC-34712) in schizophrenia: results from two 52-week open-label studies

por Correll, Christoph U., Skuban, Aleksandar, Ouyang, John, Weiller, Emmanuelle, Weiss, Catherine
Publicado 2016

PS152. Efficacy and safety of brexpiprazole (OPC-34712) as adjunctive treatment in major depressive disorder: Meta-analysis of two pivotal studies

por Eriksson, Hans, Weiller, Emmanuelle, Weiss, Catherine, Zhang, Peter, Skuban, Aleksandar, Thase, Michael E.
Publicado 2016

PM421. Efficacy and safety of brexpiprazole (OPC-34712) in acute schizophrenia: a pooled analysis of two pivotal studies

por Skuban, Aleksandar, Kane, John M., Ouyang, John, Weiss, Catherine, Weiller, Emmanuelle, Correll, Christoph U.
Publicado 2016

A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder

por Hobart, Mary, Zhang, Peter, Skuban, Aleksandar, Brewer, Claudette, Hefting, Nanco, Sanchez, Raymond, McQuade, Robert D.
Publicado 2019

Cognitive behavioral therapy delivered via digital mobile application for the treatment of type 2 diabetes: Rationale, design, and baseline characteristics of a randomized, control...

por Canonico, Mario Enrico, Hsia, Judith, Guthrie, Nicole L., Simmons, Martha, Mehta, Prapti, Lupinacci, Paul, Edwards, Kate, Mosesso, Kara, Gearhart, Michelle, Skuban, Aleksandar, Bonaca, Marc P., Berman, Mark A.
Publicado 2022